In case of pancreatic cancer, based on the direct correlation between Mena and EGFR, Pino et al. suggested that Mena expression could be a predictive factor of EGFR inhibitors such as Erlotinib, and this orally administrated drug is already used in combination with gemcitabine in patients with advanced pancreatic carcinomas [27]. This evidence concerns the gene EGFR and familial pancreatic carcinoma.